ST. LOUIS, Feb 17, 2004 /PRNewswire-FirstCall via COMTEX/ --GenoMed, Inc.(OTC Bulletin Board: GMED), a Next Generation Disease Management(TM) companythat uses its expertise in disease-causing genes to improve patient outcomes,today appealed to the nation's Communities of Color to consider GenoMed'streatment for preventing kidney failure. The average Black American has a ten-fold higher risk of kidney failure compared to the average White American. Theaverage life expectancy on kidney dialysis is less than five years for allAmericans.
High blood pressure, a precursor to kidney disease and the need fordialysis, is twice as prevalent among African Americans compared to whites.So is type 2 diabetes, which is even more prevalent among Hispanics and NativeAmericans. But a Black person with high blood pressure or diabetes has a fivetimes higher risk of ending up on kidney dialysis than a white person withhigh blood pressure or diabetes. Hispanics and Native Americans with diabetesalso end up on dialysis at much higher rates than whites with diabetes.
"Kidney failure always begins while a patient is still being treated by aprimary care physician for diabetes or high blood pressure," said David W.Moskowitz, M.D., GenoMed Chairman, CEO and Chief Medical Officer. "If we canenroll this patient in our Clinical Outcomes Improvement Program(TM), beforethe person has lost more than half of their kidney function, we can restorelost kidney function ... and save lives."
Dr. Moskowitz has written extensively on this topic in respected peer-reviewed journals. GenoMed's CEO majored in Chemistry (summa cum laude) atHarvard College, Biochemistry (first class honors) at Merton College, Oxford,and received an MD (cum laude) from the Harvard-MIT Division in HealthSciences and Technology (Harvard Medical School). He trained for seven yearsin Internal Medicine and Nephrology at Washington University School ofMedicine in St. Louis before spending 11 years on the faculty of St. LouisUniversity School of Medicine. He is a noted pioneer in the field of medicalgenomics, and has been recognized for his groundbreaking treatment of diseasesassociated with the angiotensin I-converting enzyme, such as chronic renalfailure due to hypertension and type 2 diabetes.
"It saddens me when I read about an important Black individual, such asthe wonderful singer Barry White, losing his kidneys due to high bloodpressure because I know that we, as a nation, can do so much more to alleviatethis public health emergency. Continued silence on this issue is a gravedisservice to people of color who go on dialysis on rates far exceedingwhites. They need to know that a cure is available -- and has been availablefor two years already," Dr. Moskowitz said.
Dr. Moskowitz said he, and GenoMed, are available to discuss the issuewith primary care physicians, who can be trained in GenoMed's treatment, andwith leaders in the Black, Hispanic and Native American communities. "We trulywant to prevent more people from needlessly suffering and dying, not just wellknown celebrities but anyone in these communities whom we can reach,"GenoMed's CEO said.
About GenoMed
GenoMed, Inc. is a Next Generation Disease Management(TM) whose mission isto improve patient outcomes by identifying the gene pathways that causedisease. GenoMed's approach to chronic kidney failure was published in 2002 ina peer-reviewed journal, Diabetes Technology & Therapeutics, and is patent-pending. Since 2002, several hundred thousand Americans with diabetes or highblood pressure have progressed beyond the point where GenoMed could have savedtheir kidney function. It is therefore imperative for all Americans to hearthat 90% of kidney failure can now be prevented.
Safe Harbor
This press release contains forward-looking statements, including thosestatements pertaining to GenoMed, Inc.'s (the Company's) treatments. The wordsor phrases "ought to," "should," "may," or similar expressions are intended toidentify "forward-looking statements" within the meaning of the PrivateSecurities Litigation Reform Act of 1995. Actual results could differmaterially from those projected in the forward looking statements as a resultof a number of risks and uncertainties, including but not limited to: (a)whether GenoMed's approach will cause regression of early kidney failure inall patients with diabetes or high blood pressure; (b) whether primary carephysicians will learn our treatment approach; (c) whether we will havesufficient financing to conduct our research and development; and (d) othereconomic, regulatory, governmental, and technological factors. Statements madeherein are as of the date of this press release and should not be relied uponas of any subsequent date. Unless otherwise required by applicable law, wespecifically disclaim any obligation to update any forward-looking statementsto reflect occurrences, developments, unanticipated events or circumstancesafter the date of such statement.
SOURCE GenoMed, Inc.
David W. Moskowitz, MD, MA, FACP, of GenoMed Inc., +1-314-977-0115, dwmoskowitz@genomedics.com ; or Paul Knopick of E & E Communications, +1-949-707-5365, pknopick@eandecommunications.com http://www.genomedics.com Copyright (C) 2004 PR Newswire. All rights reserved.NewsProvided by COMTEX, http://www.comtex.com/
ST. LOUIS, Feb. 17 /PRNewswire-FirstCall/ -- GenoMed, Inc. (OTC Bulletin Board: GMED), a Next Generation Disease Management(TM) company that uses its expertise in disease-causing genes to improve patient outcomes, today appealed to the nation's Communities of Color to consider GenoMed's treatment for preventing kidney failure. The average Black American has a ten- fold higher risk of kidney failure compared to the average White American. The average life expectancy on kidney dialysis is less than five years for all Americans. High blood pressure, a precursor to kidney disease and the need for dialysis, is twice as prevalent among African Americans compared to whites. So is type 2 diabetes, which is even more prevalent among Hispanics and Native Americans. But a Black person with high blood pressure or diabetes has a five times higher risk of ending up on kidney dialysis than a white person with high blood pressure or diabetes. Hispanics and Native Americans with diabetes also end up on dialysis at much higher rates than whites with diabetes. "Kidney failure always begins while a patient is still being treated by a primary care physician for diabetes or high blood pressure," said David W. Moskowitz, M.D., GenoMed Chairman, CEO and Chief Medical Officer. "If we can enroll this patient in our Clinical Outcomes Improvement Program(TM), before the person has lost more than half of their kidney function, we can restore lost kidney function ... and save lives." Dr. Moskowitz has written extensively on this topic in respected peer- reviewed journals. GenoMed's CEO majored in Chemistry (summa cum laude) at Harvard College, Biochemistry (first class honors) at Merton College, Oxford, and received an MD (cum laude) from the Harvard-MIT Division in Health Sciences and Technology (Harvard Medical School). He trained for seven years in Internal Medicine and Nephrology at Washington University School of Medicine in St. Louis before spending 11 years on the faculty of St. Louis University School of Medicine. He is a noted pioneer in the field of medical genomics, and has been recognized for his groundbreaking treatment of diseases associated with the angiotensin I-converting enzyme, such as chronic renal failure due to hypertension and type 2 diabetes. "It saddens me when I read about an important Black individual, such as the wonderful singer Barry White, losing his kidneys due to high blood pressure because I know that we, as a nation, can do so much more to alleviate this public health emergency. Continued silence on this issue is a grave disservice to people of color who go on dialysis on rates far exceeding whites. They need to know that a cure is available -- and has been available for two years already," Dr. Moskowitz said. Dr. Moskowitz said he, and GenoMed, are available to discuss the issue with primary care physicians, who can be trained in GenoMed's treatment, and with leaders in the Black, Hispanic and Native American communities. "We truly want to prevent more people from needlessly suffering and dying, not just well known celebrities but anyone in these communities whom we can reach," GenoMed's CEO said.
About GenoMed GenoMed, Inc. is a Next Generation Disease Management(TM) whose mission is to improve patient outcomes by identifying the gene pathways that cause disease. GenoMed's approach to chronic kidney failure was published in 2002 in a peer-reviewed journal, Diabetes Technology & Therapeutics, and is patent- pending. Since 2002, several hundred thousand Americans with diabetes or high blood pressure have progressed beyond the point where GenoMed could have saved their kidney function. It is therefore imperative for all Americans to hear that 90% of kidney failure can now be prevented.
Safe Harbor This press release contains forward-looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company's) treatments. The words or phrases "ought to," "should," "may," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, including but not limited to: (a) whether GenoMed's approach will cause regression of early kidney failure in all patients with diabetes or high blood pressure; (b) whether primary care physicians will learn our treatment approach; (c) whether we will have sufficient financing to conduct our research and development; and (d) other economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
SOURCE GenoMed, Inc. -0- 02/17/2004 /CONTACT: David W. Moskowitz, MD, MA, FACP, of GenoMed Inc., +1-314-977-0115, dwmoskowitz@genomedics.com ; or Paul Knopick of E & E Communications, +1-949-707-5365, pknopick@eandecommunications.com / /Web site: http://www.genomedics.com / (GMED)
CO: GenoMed, Inc. ST: Missouri IN: HEA MTC OTC SU: BLK HSP
quote:Originally posted by emunahstock: gmed=adot doing nicely today!
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
